The company announced positive Phase 3 results for its multiple myeloma therapy TECVAYLI, showing significant reductions in disease progression and death risk. Its MedTech unit is gaining momentum from cardiovascular strength and new products. The company is investing in new US manufacturing plants and presented new neuropsychiatry data at a major conference. Oncology is projected to be a major future revenue driver. However, some analysis suggests it may lack the combination for an earnings beat in the upcoming report, and its MedTech segment faces lingering pressure in China.